The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral drug ...
Subscribe Login Register Log out My Profile Subscriber Services Search PGe NEWSLETTERS PG STORE ARCHIVES PUBLIC NOTICES OBITUARIES JOBS CLASSIFIEDS EVENTS PETS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results